Last reviewed · How we verify
NCT04116918
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
trial in NSCLC Stage IV in 100 participants. Status unknown.
30 September 2021
Quick facts
| Lead sponsor | Baodong Qin |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 September 2019 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across China |
Conditions studied
- NSCLC Stage IV — all drugs for NSCLC Stage IV →
- EGFR T790M-negative — all drugs for EGFR T790M-negative →
- Anlotinib — all drugs for Anlotinib →
- JS001 — all drugs for JS001 →
Sponsor
Baodong Qin — full company profile →
Who can join
Adults 18 Months to 75, any sex, with NSCLC Stage IV or EGFR T790M-negative. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Zhou F, Qiao M, Zhou C. · · 2021 · cited 177× · PMID 33177696 · DOI 10.1038/s41423-020-00577-5 -
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y, Wang H, He C. · · 2021 · cited 26× · PMID 34661758 · DOI 10.1007/s00432-021-03828-8
Verify or expand the search:
- PubMed search for NCT04116918
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC Stage IV
Currently open trials in the same condition.
- NCT07279402 — TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% · recruiting
- NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
- NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
- NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
- NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting
Other Baodong Qin trials
Trials by the same sponsor.
- NCT03701607 — Effect of Chemotherapy on PD-L1 in NSCLC · unknown
- NCT03683407 — Effect of Chemotherapy on TMB in NSCLC · unknown
- NCT03239015 — Efficacy and Safety of Precision Therapy in Refractory Tumor · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04116918 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baodong Qin
- Last refreshed: 7 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04116918.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing